Answers are grounded in this paper and cite their sources.
Breast cancer is one of the primary causes of morbidity and mortality in Indonesia. Based on molecular characteristics, it is classified into several subtypes: Luminal A, Luminal B (HER2-positive and HER2-negative), HER2-positive (HER2+) non-Luminal, and triple-negative breast cancer (TNBC). Luminal A typically has a better prognosis than Luminal B. Extended Inflammatory Parameters (EIP) are novel markers reflecting cell activation in inflammation. These include activated neutrophils (NEUT-GI, NEUT-RI), activated lymphocytes (RE-LYMP), and antibody-synthesizing lymphocytes (AS-LYMP). This study aimed to compare EIP values between HER2-positive (HER2+) and HER2-negative (HER2-) breast cancer patients. We conducted a retrospective, cross-sectional study using medical records and the laboratory information system at Dr. Hasan Sadikin General Hospital, Bandung, from July 2023 to June 2024, involving 65 subjects. We performed statistical analyses using SPSS version 23. We assessed data distribution using the Kolmogorov-Smirnov test, which indicated a non-normal distribution. Consequently, EIP comparisons across subtypes were analyzed using the Kruskal-Wallis test and Mann-Whitney tests. The results showed no significant differences in EIP among breast cancer subtypes (e.g., NEUT-GI p = 0.72; RE-LYMP% p = 0.10) or between HER2+ and HER2- groups (e.g., NEUT-RI p = 0.57; AS-LYMP# p = 0.81). In conclusion, pre-chemotherapy EIP values (NEUT-RI, NEUT-GI, RE-LYMP, AS-LYMP) do not differ significantly between breast cancer subtypes or HER2 status. Further study is necessary to clarify EIP roles in breast cancer.
No takes yet. Share an insight, caveat, or question.
Prihatni et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: